Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | GRB2 | P62993 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009160 | 0.90 | CALCRL (0.48) | CALCRLBACE1BACE2OPRD1OPRM1 | |
| SCHEMBL29790226 | 0.90 | ERAP2 (0.39) | BACE1BACE2ERBB2 | |
| SCHEMBL30973091 | 0.89 | BACE1 (0.43) | ENPEPBACE1BACE2ERBB2OPRD1 | |
| SCHEMBL30997434 | 0.89 | MME (0.38) | ENPEPBACE1BACE2OPRD1OPRM1 | |
| SCHEMBL2742710 | 0.88 | CALCRL (0.37) | CALCRLENPEPBACE1BACE2ERBB2 | |
| SCHEMBL12873177 | 0.88 | CALCRL (0.37) | CALCRLENPEPBACE1BACE2ERBB2 | |
| SCHEMBL29980611 | 0.88 | OPRM1 (0.36) | ENPEPBACE1BACE2OPRD1OPRM1 | |
| SCHEMBL29986038 | 0.88 | PDCD1LG2 (0.39) | BACE1GRB2 | |
| SCHEMBL31391114 | 0.87 | SLC6A2 (0.36) | BACE1BACE2OPRD1OPRM1 | |
| SCHEMBL30008256 | 0.87 | BACE1 (0.39) | ENPEPBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12269856-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269856-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | CALCRL 134/4885ENPEP 63/4885BACE1 1506/4885 |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | CALCRL 134/4885ENPEP 63/4885BACE1 1506/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | CALCRL 55/4885ENPEP 90/4885BACE1 1252/4885 |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | CALCRL 134/4885ENPEP 63/4885BACE1 1506/4885 |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | CALCRL 80/4885ENPEP 214/4885BACE1 3603/4885 |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | CALCRL 134/4885ENPEP 63/4885BACE1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.